Insulin-like growth factor 1 (IGF-1) is one of the most studied signaling molecules in endocrinology and cell biology. IGF-1 sits at the center of the growth hormone axis, acts through a dedicated receptor tyrosine kinase, and serves as a standard reference ligand in receptor-binding and cell-proliferation assays. This overview explains what IGF-1 is, how it is produced and regulated, how its receptor signals, and why the engineered analog IGF-1 LR3 is the form most often used as a laboratory research tool.
What Is IGF-1?
IGF-1 is a 70-amino-acid polypeptide hormone structurally related to proinsulin, sharing roughly 50 percent sequence homology with insulin. It is the principal mediator of the growth-promoting effects of growth hormone, and it circulates at nanomolar concentrations bound almost entirely to a family of carrier proteins. Because its structure, receptor, and downstream pathways are so thoroughly characterized, IGF-1 is used across cell biology, endocrinology, and metabolic research as a defined stimulus for interrogating growth-factor signaling in vitro.
The GH–IGF-1 Axis
IGF-1 is the downstream effector of the growth hormone (GH) axis. The hypothalamus releases growth hormone releasing hormone (GHRH), which stimulates the anterior pituitary to secrete GH. GH then acts on the liver and peripheral tissues to drive the synthesis and secretion of IGF-1. Circulating IGF-1 in turn feeds back on the hypothalamus and pituitary to suppress further GH release, forming a classic negative-feedback endocrine loop. This GH-to-IGF-1 relationship is why secretagogues that act upstream — GHRH analogs such as CJC-1295 and Tesamorelin, or GH secretagogue-receptor agonists such as Ipamorelin — are studied for their effect on IGF-1 output in preclinical models.
IGF-Binding Proteins and Bioavailability
In circulation, roughly three-quarters of IGF-1 is not free but bound in a ternary complex with IGF-binding protein 3 (IGFBP-3) and the acid-labile subunit. Six high-affinity IGF-binding proteins (IGFBP-1 through IGFBP-6) regulate the half-life, tissue distribution, and receptor availability of IGF-1. This binding is central to IGF-1 pharmacology: only the free fraction can engage the receptor, and in cell-culture media containing serum, IGF-binding proteins sequester much of any native IGF-1 that is added. That limitation is precisely why engineered, binding-protein-resistant analogs were developed for research use.
The IGF-1 Receptor and PI3K/Akt Signaling
IGF-1 signals through the IGF-1 receptor (IGF-1R), a transmembrane receptor tyrosine kinase assembled from two alpha and two beta subunits. Ligand binding to the extracellular alpha subunits triggers autophosphorylation of the intracellular beta-subunit kinase domains, which recruit adaptor proteins including insulin receptor substrate 1 (IRS-1) and Shc. Two principal cascades follow. The PI3K/Akt pathway drives cell survival, protein synthesis through mTOR, and glucose metabolism. The Ras/MAPK (ERK) pathway drives cell-cycle progression and proliferation. Because IGF-1R is closely related to the insulin receptor and can even form hybrid receptors with it, selectivity and cross-talk are recurring themes in this area of receptor research.
Why IGF-1 Is Studied In Vitro
IGF-1 and its analogs are used as reference ligands across a range of laboratory assays: competitive receptor-binding studies that quantify affinity, cell-proliferation and viability assays in myoblast, fibroblast, and epithelial lines, phosphorylation time-courses that track IRS-1, Akt, and ERK activation, and defined serum-free media formulations where a growth-factor supplement is required. In every case the compound is a molecular tool for probing a pathway, not a therapeutic. All such work is preclinical and in-vitro by definition.
How IGF-1 LR3 Differs from Native IGF-1
The form most commonly stocked as a research reagent is not native IGF-1 but IGF-1 LR3 (Long R3 IGF-1), an 83-amino-acid engineered analog. Two modifications distinguish it: an arginine substituted for the native glutamic acid at position 3 (the R3), and a 13-amino-acid extension added to the N-terminus (the Long portion). Together these markedly reduce the analog’s affinity for IGF-binding proteins while preserving full agonist activity at IGF-1R, which raises its effective potency in binding-protein-rich environments such as serum-containing media. The mechanism of that difference is covered in the companion note IGF-1 LR3 vs Native IGF-1, and laboratory handling is covered in the IGF-1 LR3 research overview.
Frequently Asked Questions
What is the difference between IGF-1 and insulin? IGF-1 and insulin are structurally homologous and their receptors are closely related, but they serve different primary roles: insulin is central to acute glucose homeostasis, while IGF-1 primarily mediates growth-hormone-driven anabolic and proliferative signaling. Their receptors can even form hybrid complexes, which is one reason cross-reactivity is studied carefully in receptor pharmacology.
Is IGF-1 the same as growth hormone? No. Growth hormone (somatotropin) is a separate pituitary peptide that acts upstream; IGF-1 is produced largely by the liver in response to growth hormone and carries out many of its downstream effects. They are two distinct molecules linked within a single endocrine axis.
Why is IGF-1 LR3 used instead of native IGF-1 in cell culture? Serum-containing media are rich in IGF-binding proteins that sequester native IGF-1 and blunt its activity. IGF-1 LR3 resists that binding, so a larger fraction stays free to engage the receptor, making it a more consistent research tool. Specifications are on the IGF-1 LR3 product page.
What does the IGF-1 receptor do? The IGF-1 receptor is a receptor tyrosine kinase that, on binding IGF-1, activates the PI3K/Akt and Ras/MAPK pathways to influence cell survival, protein synthesis, and proliferation in research models.
Research Use Notice
IGF-1, IGF-1 LR3, and all related compounds referenced here are supplied strictly for in-vitro and preclinical laboratory research. They are not drugs or dietary supplements, are not for human or veterinary use, and nothing in this article is a therapeutic claim or dosing recommendation. All signaling described is characterized in cell-culture and animal-model systems.